The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors

Metabolism: Clinical and Experimental

Volumn 63, Issue 10, 2014, Pages 1228-1237

  Wilding, John P H ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Kidneys; Sodium glucose co transporter 2 (SGLT2) inhibitor; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2;

DRUG EFFICACY; DRUG SAFETY; GENETIC DISORDER; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; KIDNEY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN EXPRESSION; REVIEW; UPREGULATION; DRUG ANTAGONISM; HOMEOSTASIS; KIDNEYS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR;

KIDNEYS; SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR; TYPE 2 DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; GLUCOSE; HOMEOSTASIS; HUMANS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84908254603     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.06.018     Document Type: Review

References (81)

1. R.A. Defronzo Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus Diabetes 58 2009 773 795
2. J.E. Gerich Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 27 2010 136 142
3. M. Stumvoll, U. Chintalapudi, and G. Perriello Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine J Clin Invest 96 1995 2528 2533
4. J.E. Gerich Physiology of glucose homeostasis Diabetes Obes Metab 2 2000 345 350
5. J.E. Gerich, C. Meyer, and H.J. Woerle Renal gluconeogenesis: its importance in human glucose homeostasis Diabetes Care 24 2001 382 391
6. E. Cersosimo, P. Garlick, and J. Ferretti Insulin regulation of renal glucose metabolism in humans Am J Physiol 276 1999 E78 E84
7. C. Meyer, J. Dostou, and V. Nadkarni Effects of physiological hyperinsulinemia on systemic, renal, and hepatic substrate metabolism Am J Physiol 275 1998 F915 F921
8. C. Meyer, M. Stumvoll, and S. Welle Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans Am J Physiol Endocrinol Metab 285 2003 E819 E826
9. M.Z. Shrayyef, and J.E. Gerich Normal glucose homeostasis L. Poretsky, Principles of Diabetes Mellitus 2010 Springer New York, NY 19 35
10. C. Meyer, J.M. Dostou, and S.L. Welle Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis Am J Physiol Endocrinol Metab 282 2002 E419 E427
11. E.M. Wright Renal Na(+)-glucose cotransporters Am J Physiol Renal Physiol 280 2001 F10 F18
12. E.M. Wright, B.A. Hirayama, and D.F. Loo Active sugar transport in health and disease J Intern Med 261 2007 32 43
13. G.L. Bakris, V.A. Fonseca, and K. Sharma Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications Kidney Int 75 2009 1272 1277
14. M.A. Abdul-Ghani, L. Norton, and R.A. Defronzo Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr Rev 32 2011 515 531
15. I.S. Wood, and P. Trayhurn Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins Br J Nutr 89 2003 3 9
16. H. Bays From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus Curr Med Res Opin 25 2009 671 681
17. E.M. Wright, D.D. Loo, and B.A. Hirayama Biology of human sodium glucose transporters Physiol Rev 91 2011 733 794
18. S. Nair, and J.P. Wilding Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus J Clin Endocrinol Metab 95 2010 34 42
19. C.J. Bailey Renal glucose reabsorption inhibitors to treat diabetes Trends Pharmacol Sci 32 2011 63 71
20. D. Polidori, S. Sha, and S. Mudaliar Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study Diabetes Care 36 2013 2154 2161
21. D. Polidori, S. Sha, and A. Ghosh Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus J Clin Endocrinol Metab 98 2013 E867 E871
22. Y. Liang, K. Arakawa, and K. Ueta Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models PLoS One 7 2012 e30555
23. A. Guyton, and J. Hall Textbook of Medical Physiology 2006 Elsevier Saunders Philadelphia, PA
24. K. Rave, L. Nosek, and J. Posner Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes - results of a hyperglycaemic glucose clamp study Nephrol Dial Transplant 21 2006 2166 2171
25. B. Ruhnau, O.K. Faber, and K. Borch-Johnsen Renal threshold for glucose in non-insulin-dependent diabetic patients Diabetes Res Clin Pract 36 1997 27 33
26. S. Wolf, K. Rave, and L. Heinemann Renal glucose excretion and tubular reabsorption rate related to blood glucose in subjects with type 2 diabetes with a critical reappraisal of the "renal glucose threshold" model Horm Metab Res 41 2009 600 604
27. D. Polidori, S. Sha, and T. Sarich Canagliflozin lowers the renal threshold for glucose excretion in lean, obese and type 2 diabetic subjects [abstract] Diabetologia 53 2010 S350
28. D. Devineni, L. Morrow, and M. Hompesch Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin Diabetes Obes Metab 14 2012 539 545
29. S.J. Farber, E.Y. Berger, and D.P. Earle Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose J Clin Invest 30 1951 125 129
30. C.E. Mogensen Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects Scand J Clin Lab Invest 28 1971 101 109
31. H. Rahmoune, P.W. Thompson, and J.M. Ward Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 2005 3427 3434
32. S. Vestri, M.M. Okamoto, and H.S. de Freitas Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat J Membr Biol 182 2001 105 112
33. H.S. Freitas, G.F. Anhe, and K.F. Melo Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity Endocrinology 149 2008 717 724
34. N.M. Tabatabai, M. Sharma, and S.S. Blumenthal Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats Diabetes Res Clin Pract 83 2009 e27 e30
35. H. Beck-Nielsen, O. Hother-Nielsen, and P. Staehr Is hepatic glucose production increased in type 2 diabetes mellitus? Curr Diab Rep 2 2002 231 236
36. E. Turk, B. Zabel, and S. Mundlos Glucose/galactose malabsorption caused by a defect in the Na +/glucose cotransporter Nature 350 1991 354 356
37. J. Calado, Y. Sznajer, and D. Metzger Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion Nephrol Dial Transplant 23 2008 3874 3879
38. R. Santer, M. Kinner, and C.L. Lassen Molecular analysis of the SGLT2 gene in patients with renal glucosuria J Am Soc Nephrol 14 2003 2873 2882
39. R. Santer, and J. Calado Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target Clin J Am Soc Nephrol 5 2010 133 141
40. B. Zambrowicz, J. Freiman, and P.M. Brown LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial Clin Pharmacol Ther 92 2012 158 169
41. INVOKANA™ (canagliflozin) tablets, for oral use [package insert] 2013 Janssen Pharmaceuticals Titusville, NJ
42. Summary of Product Characteristics Forxiga 5 mg and 10 mg film-coated tablets 2012 Bristol-Myers Squibb/AstraZeneca EEIG Middlesex, United Kingdom
43. E. Kurosaki, and H. Ogasawara Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data Pharmacol Ther 139 2013 51 59
44. Z. Miao, G. Nucci, and N. Amin Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects Drug Metab Dispos 41 2013 445 456
45. E. Ferrannini, L. Seman, and E. Seewaldt-Becker A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes Metab 15 2013 721 728
46. FARXIGA™ (dapagliflozin) tablets, for oral use [package insert] 2014 Bristol-Myers Squibb Company Princeton, NJ
47. INVOKANA™ (canagliflozin) tablets, for oral use [Summary of Product Characteristics] 2013 Janssen-Cilag International NV Beerse, Belgium
48. D. Devineni, C.R. Curtin, and D. Polidori Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus J Clin Pharmacol 53 2013 601 610
49. S. Sha, D. Devineni, and A. Ghosh Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 13 2011 669 672
50. J. Rosenstock, N. Aggarwal, and D. Polidori Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 2012 1232 1238
51. D. Polidori, S. Sha, and Y. Liang Renal glucose reabsorption in type 2 diabetes mellitus: new insights from studies with canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor Poster presented at: the World Diabetes Congress of the International Diabetes Federation; December 4-8, 2011; Dubai, United Arab Emirates 2011
52. P. Stein, J.K. Berg, and L. Morrow Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes mellitus (T2DM) by a non-renal mechanism [abstract] Diabetes 61 2012
53. S. Nomura, S. Sakamaki, and M. Hongu Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus J Med Chem 53 2010 6355 6360
54. B. Bode, K. Stenlöf, and D. Sullivan Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial Hosp Pract 41 2013 72 84
55. W.T. Cefalu, L.A. Leiter, and K.-H. Yoon Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 2013 941 950
56. G. Schernthaner, J.L. Gross, and J. Rosenstock Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial Diabetes Care 36 2013 2508 2515
57. K. Stenlöf, W.T. Cefalu, and K.-A. Kim Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 2013 372 382
58. J.F. Yale, G. Bakris, and B. Cariou Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 2013 463 473
59. F.J. Lavalle-González, A. Januszewicz, and J. Davidson Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 56 2013 2582 2592
60. J.P. Wilding, G. Charpentier, and P. Hollander Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 67 2013 1267 1282
61. W.T. Cefalu, L.A. Leiter, and K.-H. Yoon Canagliflozin (CANA) demonstrates durable glycemic improvements over 104 weeks versus glimepiride (GLIM) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) [abstract] Diabetes 62 2013 LB18
62. B. Komoroski, N. Vachharajani, and D. Boulton Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 85 2009 520 526
63. B. Komoroski, N. Vachharajani, and Y. Feng Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 85 2009 513 519
64. E. Ferrannini, S.J. Ramos, and A. Salsali Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 2010 2217 2224
65. C.J. Bailey, J.L. Gross, and A. Pieters Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
66. K. Strojek, K.H. Yoon, and V. Hruba Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 13 2011 928 938
67. J. Rosenstock, M. Vico, and L. Wei Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 35 2012 1473 1478
68. S. Del Prato, M.A. Nauck, and S. Duran-Garcia Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data [abstract] Diabetes 62 2013 LB17
69. L.E. Nicolle, G. Capuano, and A. Fung Urinary tract infection in randomized Phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor Postgrad Med 126 2014 7 17
70. K.M. Johnsson, A. Ptaszynska, and B. Schmitz Urinary tract infections in patients with diabetes treated with dapagliflozin J Diabetes Complications 27 2013 473 478
71. K.M. Johnsson, A. Ptaszynska, and B. Schmitz Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin J Diabetes Complications 27 2013 479 484
72. P. Nyirjesy, J.D. Sobel, and A. Fung Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies Curr Med Res Opin 30 2014 1109 1119
73. A. Ptaszynska, A.-G. Chalamandaris, and J.E. Sugg Effect of dapagliflozin on renal function [abstract] Diabetes 61 2012 1098-P
74. C.J. Bailey, J.L. Gross, and D. Hennicken Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial BMC Med 11 2013 43
75. E. Ferrannini, E. Muscelli, and S. Frascerra Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 124 2014 499 508
76. A. Merovci, C. Solis-Herrera, and G. Daniele Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production J Clin Invest 124 2014 509 514
77. M.A. Nauck, P.S. Del, and J.J. Meier Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 2011 2015 2022
78. J. Bolinder, O. Ljunggren, and J. Kullberg Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 97 2012 1020 1031
79. R.R. Henry, J. Rosenstock, and A.-G. Chalamandaris Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study [abstract] Diabetes 62 2013 LB20
80. B.A. Perkins, D.Z. Cherney, and H. Partridge Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial Diabetes Care 37 2014 1480 1483
81. R.A. Defronzo, M. Hompesch, and S. Kasichayanula Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes Diabetes Care 36 2013 3169 3176